Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 11-Mar-20 5:39 PM View:  | Harsch Mutya CLO and General Counsel | Foamix Pharmaceuticals Ltd. (FOMX) | 09-Mar-20 | Disposition | 98,232 | -- | -- | (100%) 98.23K to 0 | |
| 11-Mar-20 5:39 PM View: | Hirsch Stanley Director | Foamix Pharmaceuticals Ltd. (FOMX) | 09-Mar-20 | Disposition | 52,842 | -- | -- | (15%) 353.37K to 300.53K | |
| 11-Mar-20 5:39 PM View: | Kazanchyan Anna Director | Foamix Pharmaceuticals Ltd. (FOMX) | 09-Mar-20 | Disposition | 58,744 | -- | -- | (100%) 58.74K to 0 | |
| 11-Mar-20 5:41 PM View: | Stuart Iain Chief Scientific Officer | Foamix Pharmaceuticals Ltd. (FOMX) | 09-Mar-20 | Disposition | 103,636 | -- | -- | (100%) 103.64K to 0 | |
| 11-Mar-20 5:39 PM View: | Hirsch Stanley Director | Foamix Pharmaceuticals Ltd. (FOMX) | 09-Mar-20 | Disposition | 182,500 | -- | -- | (61%) 300.53K to 118.03K | |
| 11-Mar-20 5:41 PM View: | Wiley Matthew T. Chief Commercial Officer | Foamix Pharmaceuticals Ltd. (FOMX) | 09-Mar-20 | Disposition | 114,074 | -- | -- | (100%) 114.07K to 0 | |
| 11-Mar-20 5:40 PM View: | Schwartz Aharon Director | Foamix Pharmaceuticals Ltd. (FOMX) | 09-Mar-20 | Disposition | 112,200 | -- | -- | (100%) 112.2K to 0 | |
| 18-Mar-20 9:52 AM View: | Stern Stanley Director | Foamix Pharmaceuticals Ltd. (FOMX) | 09-Mar-20 | Disposition | 42,359 | -- | -- | (100%) 42.36K to 0 | |
| 11-Mar-20 5:39 PM View: | Hirsch Stanley Director | Foamix Pharmaceuticals Ltd. (FOMX) | 09-Mar-20 | Disposition | 59,016 | -- | -- | (50%) 118.03K to 59.02K | |
| 11-Mar-20 5:38 PM View: | Domzalski David CEO Director | Foamix Pharmaceuticals Ltd. (FOMX) | 09-Mar-20 | Disposition | 324,028 | -- | -- | (100%) 324.03K to 0 | |
| 11-Mar-20 5:38 PM View: | Hadar Ilan CFO & Country Manager | Foamix Pharmaceuticals Ltd. (FOMX) | 09-Mar-20 | Disposition | 130,578 | -- | -- | (100%) 130.58K to 0 | |
| 11-Mar-20 5:37 PM View: | Bruno Anthony D Director | Foamix Pharmaceuticals Ltd. (FOMX) | 09-Mar-20 | Disposition | 75,007 | -- | -- | (100%) 75.01K to 0 | |
| 03-Mar-20 4:39 PM View: | Wiley Matthew T. Chief Commercial Officer | Foamix Pharmaceuticals Ltd. (FOMX) | 02-Mar-20 | Grant | 1,993 | $2.68 | $5,336.26 | 2% 112.08K to 114.07K | (< 1%) |
| 03-Mar-20 4:38 PM View: | Domzalski David CEO Director | Foamix Pharmaceuticals Ltd. (FOMX) | 02-Mar-20 | Grant | 4,705 | $2.68 | $12,597.60 | 1% 319.32K to 324.03K | (< 1%) |
| 03-Mar-20 4:38 PM View: | Harsch Mutya CLO and General Counsel | Foamix Pharmaceuticals Ltd. (FOMX) | 02-Mar-20 | Grant | 1,761 | $2.68 | $4,715.08 | 2% 96.47K to 98.23K | (< 1%) |
| 03-Mar-20 4:36 PM View: | Stern Stanley Director | Foamix Pharmaceuticals Ltd. (FOMX) | 27-Feb-20 | Grant | 14,164 | -- | -- | 50% 28.2K to 42.36K | |
| 03-Mar-20 4:31 PM View: | Bruno Anthony D Director | Foamix Pharmaceuticals Ltd. (FOMX) | 27-Feb-20 | Grant | 5,312 | -- | -- | 8% 69.69K to 75.01K | |
| 03-Mar-20 4:32 PM View: | Hirsch Stanley Director | Foamix Pharmaceuticals Ltd. (FOMX) | 27-Feb-20 | Grant | 42,493 | -- | -- | 17% 251.87K to 294.36K | |
| 03-Mar-20 4:32 PM View: | Kazanchyan Anna Director | Foamix Pharmaceuticals Ltd. (FOMX) | 27-Feb-20 | Grant | 21,246 | -- | -- | 57% 37.5K to 58.74K | |
| 24-Feb-20 6:39 PM View: | Stuart Iain Chief Scientific Officer | Foamix Pharmaceuticals Ltd. (FOMX) | 24-Feb-20 | Grant | 41,299 | -- | -- | 66% 62.34K to 103.64K | |
| 24-Feb-20 6:38 PM View: | Domzalski David CEO Director | Foamix Pharmaceuticals Ltd. (FOMX) | 24-Feb-20 | Grant | 103,248 | -- | -- | 48% 216.07K to 319.32K | |
| 24-Feb-20 6:38 PM View: | Harsch Mutya CLO and General Counsel | Foamix Pharmaceuticals Ltd. (FOMX) | 24-Feb-20 | Grant | 41,299 | -- | -- | 75% 55.17K to 96.47K | |
| 24-Feb-20 6:38 PM View: | Hadar Ilan CFO & Country Manager | Foamix Pharmaceuticals Ltd. (FOMX) | 24-Feb-20 | Grant | 41,299 | -- | -- | 46% 89.28K to 130.58K | |
| 24-Feb-20 6:39 PM View: | Wiley Matthew T. Chief Commercial Officer | Foamix Pharmaceuticals Ltd. (FOMX) | 24-Feb-20 | Grant | 41,299 | -- | -- | 58% 70.78K to 112.08K | |
| 03-Jan-20 5:23 PM View: | Stuart Iain Chief Scientific Officer | Foamix Pharmaceuticals Ltd. (FOMX) | 31-Dec-19 | Payment of Exercise | 514 | $3.28 | $1,685.92 | (< 1%) 62.85K to 62.34K | |
| 03-Jan-20 5:23 PM View: | Harsch Mutya CLO and General Counsel | Foamix Pharmaceuticals Ltd. (FOMX) | 31-Dec-19 | Payment of Exercise | 618 | $3.28 | $2,027.04 | (1%) 55.79K to 55.17K | |
| 03-Jan-20 5:22 PM View: | Domzalski David CEO Director | Foamix Pharmaceuticals Ltd. (FOMX) | 31-Dec-19 | Payment of Exercise | 2,751 | $3.28 | $9,023.28 | (1%) 218.83K to 216.07K | |
| 03-Jan-20 5:24 PM View: | Wiley Matthew T. Chief Commercial Officer | Foamix Pharmaceuticals Ltd. (FOMX) | 31-Dec-19 | Payment of Exercise | 2,500 | $3.28 | $8,200.00 | (3%) 73.28K to 70.78K | |
| 03-Dec-19 4:31 PM View: | Wiley Matthew T. Chief Commercial Officer | Foamix Pharmaceuticals Ltd. (FOMX) | 29-Nov-19 | Grant | 9,842 | $2.16 | $21,248.90 | 16% 63.44K to 73.28K | |
| 03-Dec-19 4:32 PM View: | Domzalski David CEO Director | Foamix Pharmaceuticals Ltd. (FOMX) | 29-Nov-19 | Grant | 9,842 | $2.16 | $21,248.90 | 5% 208.98K to 218.83K | |
| 03-Dec-19 4:30 PM View: | Harsch Mutya CLO and General Counsel | Foamix Pharmaceuticals Ltd. (FOMX) | 29-Nov-19 | Grant | 4,284 | $2.16 | $9,249.16 | 8% 51.51K to 55.79K | |
| 05-Nov-19 4:32 PM View: | Hirsch Stanley Director | Foamix Pharmaceuticals Ltd. (FOMX) | 04-Nov-19 | Option Exercise | 32,500 | $0.62 | $20,150.00 | 15% 219.37K to 251.87K | |
| 17-Oct-19 4:11 PM View: | Hirsch Stanley Director | Foamix Pharmaceuticals Ltd. (FOMX) | 15-Oct-19 | Option Exercise | 90,000 | $0.62 | $55,800.00 | 70% 129.37K to 219.37K | |
| 02-Oct-19 4:19 PM View: | Harsch Mutya CLO and General Counsel | Foamix Pharmaceuticals Ltd. (FOMX) | 30-Sep-19 | Payment of Exercise | 463 | $3.07 | $1,421.41 | (< 1%) 51.97K to 51.51K | |
| 02-Oct-19 4:18 PM View: | Domzalski David CEO Director | Foamix Pharmaceuticals Ltd. (FOMX) | 30-Sep-19 | Payment of Exercise | 2,256 | $3.07 | $6,925.92 | (1%) 211.24K to 208.98K | |
| 02-Oct-19 4:20 PM View: | Stuart Iain Chief Scientific Officer | Foamix Pharmaceuticals Ltd. (FOMX) | 30-Sep-19 | Payment of Exercise | 673 | $3.07 | $2,066.11 | (1%) 63.52K to 62.85K | |
| 11-Sep-19 5:12 PM View: | Hadar Ilan CFO & Country Manager | Foamix Pharmaceuticals Ltd. (FOMX) | 10-Sep-19 | Private Sale (Planned) | 34,392 | $3.50 | $120,375.00 | (28%) 123.67K to 89.28K | |
| 11-Sep-19 5:12 PM View: | Hadar Ilan CFO & Country Manager | Foamix Pharmaceuticals Ltd. (FOMX) | 09-Sep-19 | Private Sale (Planned) | 9,420 | $3.50 | $32,990.70 | (7%) 133.09K to 123.67K | |
| 28-Aug-19 4:36 PM View: | Kazanchyan Anna Director | Foamix Pharmaceuticals Ltd. (FOMX) | 26-Aug-19 | Private Sale | 7,049 | $3.27 | $23,050.20 | (16%) 44.55K to 37.5K | |
| 14-Aug-19 2:59 PM View: | Hirsch Stanley Director | Foamix Pharmaceuticals Ltd. (FOMX) | 13-Aug-19 | Option Exercise | 60,000 | $0.62 | $37,200.00 | 86% 69.36K to 129.37K | |
| 17-Jul-19 4:40 PM View: | Kazanchyan Anna Director | Foamix Pharmaceuticals Ltd. (FOMX) | 15-Jul-19 | Sale (Planned) | 808 | $2.31 | $1,866.48 | (2%) 45.35K to 44.55K | |
| 03-Jul-19 4:27 PM View: | Domzalski David CEO Director | Foamix Pharmaceuticals Ltd. (FOMX) | 01-Jul-19 | Market Sale | 3,355 | $2.35 | $7,884.25 | (2%) 214.59K to 211.24K | (13%) |
| 03-Jul-19 4:28 PM View: | Harsch Mutya CLO and General Counsel | Foamix Pharmaceuticals Ltd. (FOMX) | 01-Jul-19 | Market Sale | 639 | $2.35 | $1,501.65 | (1%) 52.61K to 51.97K | (13%) |
| 03-Jul-19 4:26 PM View: | Stuart Iain Chief Scientific Officer | Foamix Pharmaceuticals Ltd. (FOMX) | 01-Jul-19 | Market Sale | 951 | $2.35 | $2,234.85 | (1%) 64.47K to 63.52K | (13%) |
| 20-May-19 6:35 PM View: | Kazanchyan Anna Director | Foamix Pharmaceuticals Ltd. (FOMX) | 20-May-19 | Market Sale (Planned) | 10,600 | $2.61 | $27,666.00 | (19%) 55.95K to 45.35K | |
| 08-Jul-19 4:50 PM View: | Stern Stanley Director | Foamix Pharmaceuticals Ltd. (FOMX) | 16-May-19 | Grant | 28,195 | -- | -- | 100% 0 to 28.2K | |
| 20-May-19 6:41 PM View: | Bruno Anthony D Director | Foamix Pharmaceuticals Ltd. (FOMX) | 16-May-19 | Grant | 28,195 | -- | -- | 68% 41.5K to 69.69K | |
| 20-May-19 6:34 PM View: | Hirsch Stanley Director | Foamix Pharmaceuticals Ltd. (FOMX) | 16-May-19 | Grant | 56,391 | -- | -- | 435% 12.97K to 69.36K | |
| 20-May-19 6:35 PM View: | Kazanchyan Anna Director | Foamix Pharmaceuticals Ltd. (FOMX) | 16-May-19 | Grant | 28,195 | -- | -- | 102% 27.76K to 55.95K | |
| 03-Apr-19 4:40 PM View: | Domzalski David CEO Director | Foamix Pharmaceuticals Ltd. (FOMX) | 01-Apr-19 | Market Sale | 5,096 | $3.75 | $19,110.00 | (2%) 219.69K to 214.59K | (8%) |
